Shanghai Kaibao Pharmaceutical Net Asset Quality Index
Shanghai Kaibao Pharmaceutical net asset quality index. Shanghai Kaibao Pharmaceutical (300039) has a Net Asset Quality Index of 93.3% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.59 Billion minus total liabilities of CN¥308.94 Million yields net assets of CN¥4.29 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 300039 net assets for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Shanghai Kaibao Pharmaceutical (2006–2025)
Net asset quality index of Shanghai Kaibao Pharmaceutical from 2006 to 2025. This chart shows how Shanghai Kaibao Pharmaceutical's Net Asset Quality Index has evolved across 20 annual periods from 2006 to 2025. As of June 2026, the index stands at 93.3%, representing net assets of CN¥4.29 Billion against total assets of CN¥4.59 Billion CNY. Check Shanghai Kaibao Pharmaceutical PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Shanghai Kaibao Pharmaceutical Net Asset Quality Index by Year (2006–2025)
Shanghai Kaibao Pharmaceutical net asset quality index by year from 2006 to 2025. The table below presents the year-by-year Net Asset Quality Index for Shanghai Kaibao Pharmaceutical from 2006 to 2025, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Shanghai Kaibao Pharmaceutical (300039) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 92.5% | CN¥4.42 Billion | CN¥4.78 Billion | CN¥359.64 Million | ▲ +1.7 pp |
| 2024 | 90.8% | CN¥4.10 Billion | CN¥4.52 Billion | CN¥415.45 Million | ▲ +2.7 pp |
| 2023 | 88.1% | CN¥4.03 Billion | CN¥4.58 Billion | CN¥546.82 Million | ▼ -0.2 pp |
| 2022 | 88.3% | CN¥3.76 Billion | CN¥4.26 Billion | CN¥498.24 Million | ▼ -2.4 pp |
| 2021 | 90.7% | CN¥3.04 Billion | CN¥3.36 Billion | CN¥310.90 Million | ▲ +1.1 pp |
| 2020 | 89.6% | CN¥2.58 Billion | CN¥2.88 Billion | CN¥298.96 Million | ▼ -0.8 pp |
| 2019 | 90.4% | CN¥2.57 Billion | CN¥2.84 Billion | CN¥273.01 Million | ▼ -0.1 pp |
| 2018 | 90.5% | CN¥2.49 Billion | CN¥2.75 Billion | CN¥262.26 Million | ▲ +2.2 pp |
| 2017 | 88.3% | CN¥2.37 Billion | CN¥2.68 Billion | CN¥314.26 Million | ▲ +1.2 pp |
| 2016 | 87.0% | CN¥2.20 Billion | CN¥2.53 Billion | CN¥327.61 Million | ▲ +4.4 pp |
| 2015 | 82.6% | CN¥2.01 Billion | CN¥2.43 Billion | CN¥421.16 Million | ▼ -6.4 pp |
| 2014 | 89.0% | CN¥1.88 Billion | CN¥2.12 Billion | CN¥232.72 Million | ▼ -1.7 pp |
| 2013 | 90.7% | CN¥1.61 Billion | CN¥1.77 Billion | CN¥164.72 Million | ▼ -0.2 pp |
| 2012 | 90.9% | CN¥1.42 Billion | CN¥1.56 Billion | CN¥142.29 Million | ▼ -1.0 pp |
| 2011 | 91.9% | CN¥1.33 Billion | CN¥1.45 Billion | CN¥117.97 Million | ▲ +1.6 pp |
| 2010 | 90.3% | CN¥1.24 Billion | CN¥1.37 Billion | CN¥133.39 Million | ▲ +5.1 pp |
| 2009 | 85.2% | CN¥1.15 Billion | CN¥1.35 Billion | CN¥199.20 Million | ▲ +30.0 pp |
| 2008 | 55.2% | CN¥126.92 Million | CN¥229.88 Million | CN¥102.95 Million | ▲ +7.6 pp |
| 2007 | 47.6% | CN¥76.96 Million | CN¥161.61 Million | CN¥84.64 Million | ▲ +13.5 pp |
| 2006 | 34.2% | CN¥37.24 Million | CN¥109.03 Million | CN¥71.80 Million | — |